Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York Carolina Biooncology Institute, Huntersville, North Carolina South Korea
Chungnam National University Hospital, Daejeon, Daejeon The Catholic University of Korea St. Vincent's Hospital, Suwon, Kyeonggi-do Korea University Anam Hospital, Seoul, Seongbuk-gu Yonsei University Health System, Severance Hospital, Seoul Yonsei University Health System, Severance Hospital, Seoul Asan Medical Center, Seoul